Drugs / GPRC5D-CD19 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06298266 | Mar 2024 → May 2026 overdue | refractory plasma cell neoplasm | Guangdong Second Provincial General Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPRC5D-CD19 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06298266 ↗ |
| Modality | Cell therapy | “GPRC5D-CD19 CAR T cells” NCT06298266 ↗ |
| Route | Intravenous | “Administration method: intravenous infusion” NCT06298266 ↗ |
| Target | CD19 | “Anti-GPRC5D-CD19-CAR-T” NCT06298266 ↗ |
| Target | GPRC5D | “Anti-GPRC5D-CD19-CAR-T” NCT06298266 ↗ |